Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 12/20 | 0.43 |
| ▸ | CA1 | P00915 | 10/20 | 0.43 |
| ▸ | CA9 | Q16790 | 5/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 3/20 | 0.39 |
| ▸ | CA7 | P43166 | 2/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | PTGES2 | Q9H7Z7 | 2/20 | 0.39 |
| ▸ | CA3 | P07451 | 1/20 | 0.37 |
| ▸ | CA6 | P23280 | 1/20 | 0.37 |
| ▸ | CA5A | P35218 | 1/20 | 0.37 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4575696 | 0.89 | PTGS1 (0.56) | PTGS1PTGS2CA2CA1CA9 | |
| SCHEMBL8099531 | 0.88 | CA1 (0.41) | PTGS2CA2CA1CA9APP | |
| SCHEMBL8101100 | 0.85 | CA2 (0.44) | PTGS1PTGS2CA2CA1CA9 | |
| SCHEMBL8101785 | 0.84 | CA2 (0.48) | PTGS1PTGS2CA2CA1CA9 | |
| SCHEMBL8092090 | 0.83 | PTGS2 (0.44) | PTGS1PTGS2CA2CA1CA9 | |
| SCHEMBL8098762 | 0.81 | PTGS1 (0.45) | PTGS1PTGS2CA2CA1CA9 | |
| SCHEMBL8479236 | 0.81 | PTGS1 (0.44) | PTGS1PTGS2CA2CA1CA9 | |
| SCHEMBL8098886 | 0.81 | CA2 (0.46) | CA2CA1CA9CA12CA7 | |
| SCHEMBL8100630 | 0.80 | CA2 (0.44) | PTGS1PTGS2CA2CA1CA9 | |
| SCHEMBL8101110 | 0.80 | CA2 (0.44) | PTGS1PTGS2CA2CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080027011-A1 | Homogeneous paste and gel formulations | MERIAL LIMITED | 2008-01-31 | — | — | US | disclosed |
| EP-0848703-B1 | DERIVATIVES OF BENZOSULPHONAMIDES AS INHIBITORS OF THE ENZYME CYCLO-OXYGENASE II | NYCOMED AUSTRIA GMBH (AT) | 2000-09-27 | — | — | EP | disclosed |
| US-6004948-A | NON-STEROIDAL ANTIINFLAMMATORY AGENTS; SIDE EFFECT REDUCTION | NYCOMED AUSTRIA GMBH (AT) | 1999-12-21 | — | — | US | disclosed |
| EP-0848703-A1 | DERIVATIVES OF BENZOSULPHONAMIDES AS INHIBITORS OF THE ENZYME CYCLO-OXYGENASE II | Nycomed Austria GmbH (AT) | 1998-06-24 | — | — | EP | disclosed |
| WO-1997003953-A1 | DERIVATIVES OF BENZOSULPHONAMIDES AS INHIBITORS OF THE ENZYME CYCLO-OXYGENASE II | NYCOMED AUSTRIA GMBH (AT) | 1997-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027011-A1 | Homogeneous paste and gel formulations | EPX, CAT, PEF1 | PTGS1 101/4885PTGS2 329/4885CA2 3916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.